Daily Briefing for November 13, 2026

American Cancer Society now urges PSA tests every 2 years from age 50

The voices on this episode are generated, and so is the script, from the day's post at Physician in the Loop. Every fact in the post links to its source.

Read the post and its sources

Get the free email briefing

The American Cancer Society on Thursday dropped its 16-year-old shared-decision stance on prostate cancer screening and now recommends a PSA test every two years for average-risk men 50 to 69, the society said.

Black men and men with a strong family history are to be screened every year from 45, and the guideline sets PSA thresholds, a repeat test and MRI or a biomarker before biopsy. Separately, a Doximity survey of 3,379 physicians found that 52% use AI for work every day and about three in four caught it in a factual error in the past year, and a BPROAD trial analysis in The BMJ found that a systolic target under 120 mm Hg did not reduce dementia or mild cognitive impairment in type 2 diabetes.

In this episode

• American Cancer Society now recommends PSA screening every 2 years from 50 to 69, ending its 2010 shared-decision stance
• Half of U.S. physicians now use AI every day, and three in four caught it in a factual error this year, Doximity survey finds
• A systolic target under 120 did not lower dementia or mild cognitive impairment in 12,434 adults with type 2 diabetes
• FDA clears AI that flags brain aneurysms larger than 3 mm on head CT angiography and tracks their growth between scans
• MDCalc launches CrossCover, which strips patient identifiers from clinicians' questions to medical AI chatbots